Notably, the introduction of second-generation drugs in this class, such as alectinib and brigatinib, along with third-generation lorlatinib, has expanded treatment options for ALK-mutant lung cancer, surpassing the previous use of crizotinib [8]. This evidence concerns the gene ALK and lung carcinoma.